Extrafine beclometasone diproprionate/formoterol fumarate: A review of its effects in chronic obstructive pulmonary disease

npj Primary Care Respiratory Medicine

Volumn 26, Issue , 2016, Pages

  Singh, Dave ^a   Corradi, Massimo ^b   Spinola, Monica ^c   Petruzzelli, Stefano ^c   Papi, Alberto ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF PARMA   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; BECLOMETASONE; FORMOTEROL FUMARATE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; DISEASE EXACERBATION; DRUG EFFICACY; EOSINOPHIL; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; BECLOMETHASONE; DRUG COMBINATIONS; FORMOTEROL FUMARATE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84975484252     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/npjpcrm.2016.30     Document Type: Review

References (47)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available at http://www.goldcopd.org/ (2015).
2. Calverley, P. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361, 449-456 (2003).
3. Calverley, P. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 22, 912-929 (2003).
4. Ferguson, G. T. et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir. Med. 102, 1099-1108 (2008).
5. Szafranski, W. et al. Efficacy and safety of budesonide-formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 74-81 (2003).
6. Dransfield, M. T. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir. Med. 1, 210-223 (2013).
7. Rennard, S. I. et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69, 549-565 (2009).
8. Boulet, L. P. et al. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur. Respir. J. 11, 1091-1097 (1998).
9. Tan, K. S., McFarlane, L. C. & Lipworth, B. J. Concomitant administration of lowdose prednisolone protects against in vivo beta-2-adrenoceptor subsensitivity induced by regular formoterol. Chest 113, 34-41 (1998).
10. Aziz, I. & Lipworth, B. J. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and b2-adrenoceptor down-regulation after regular inhaled formoterol. Chest 115, 623-628 (1999).
11. Haque, R. et al. Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J. Allergy Clin. Immunol. 132, 1166-1173 (2013).
12. Calverley, P. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007).
13. Celli, B. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 178, 332-338 (2008).
14. Vestbo, J. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 387, 1817-1826 (2016).
15. Dhillon, S. & Keating, G. M. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs 66, 1475-1483 (2006).
16. Hogg, J. C. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 2645-2653 (2004).
17. Aggarwal, B. & Gogtay, J. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence. Expert Rev. Respir. Med. 8, 349-356 (2014).
18. De Backer, W. et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol. Med. Pulm. Drug Deliv. 23, 137-148 (2010).
19. De Backer, J. et al. The effects of extrafine beclometasone/formoterol (bdp/f) on lung function, dyspnea, hyperinflation, and airway geometry in copd patients: novel insight using functional respiratory imaging. J. Aerosol. Med. Pulm. Drug. Deliv. 28, 88-99 (2014).
20. Calverley, P. M. et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir. Med. 104, 1858-1868 (2010).
21. Cazzola, M. et al. ATS/ERS Task Force Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 31, 416-468 (2008).
22. Donohue, J. F. Minimal clinically important differences in COPD lung function. COPD 2, 111-124 (2005).
23. Miravitlles, M. et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2-year follow up study. Thorax 59, 387-395 (2004).
24. Hurst, J. R. et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 179, 369-374 (2009).
25. Langsetmo, L., Platt, R. W., Ernst, P. & Bourbeau, J. Under-reporting exacerbation of chronic obstructive pulmonary disease in a long-term cohort. Am. J. Respir Crit. Care Med. 177, 396-401 (2008).
26. Vijayasaretha, K. & Stockley, R. A. Reported and unreported exacerbations of COPD: analysis by diary card. Chest 133, 34-41 (2008).
27. European centre for disease prevention and control. Available at http://ecdc.europa.eu/en/publications/surveillance-reports/influenza.
28. Wedzicha, J. A. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 108, 1153-1162 (2014).
29. Jenkins, C. R. et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur. Respir. J. 39, 38-45 (2012).
30. Hurst, J. R. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363, 1128-1138 (2010).
31. Leidy, N. K. et al. Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir. Res. 15, 124 (2006).
32. Neyt, M., Devriese, S., Thiry, N. & Van den Bruel, A. Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm. Med. 15, 10-47 (2010).
33. Herland, K., Akselsen, J. P., Skjonsberg, O. H. & Bjermer, L. How representative are clinical study patients with asthma or COPD for a larger 'real life' population of patients with obstructive lung disease? Respir. Med. 99, 11-19 (2005).
34. Pascoe, S., Locantore, N., Dransfield, M. T., Barnes, N. C. & Pavord, I. D. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 3, 435-442 (2015).
35. Siddiqui, S. et al. Blood Eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 192, 523-525 (2015).
36. Singh, D. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 44, 1697-1700 (2014).
37. Singh, D. et al. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm. Med. 12, 14 (2014).
38. Matera, M. G., Cardaci, V., Cazzola, M. & Rogliani, P. Safety of inhaled corticosteroids for treating chronic pulmonary disease. Expert Opin. Drug. Saf. 14, 533-541 (2015).
39. Cazzola, M. et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. 7, 103-107 (1994).
40. Stephenson, J. J. et al. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 10, 577-586 (2015).
41. Kew, K. M. & Seniukovich, A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 10, 3 (2014).
42. Festic, E. & Scanlon, P. D. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? Am. J. Respir. Crit. Care Med. 15, 141-148 (2015).
43. Singh, S., Amin, A. V. & Loke, Y. K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch. Intern. Med. 169, 219-229 (2009).
44. Sharafkhaneh, A., Southard, J. G., Goldman, M., Uryniak, T. & Martin, U. J. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir. Med. 106, 257-268 (2012).
45. Kardos, P., Wencker, M., Glaab, T. & Vogelmeier, C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 144-149 (2007).
46. Anzueto, A. et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 6, 320-329 (2009).
47. Calverley, P. M. Minimal clinically important difference-exacerbations of COPD. COPD 2, 143-148 (2005).